Southwest oncology group strategies in prostatic carcinoma

Seminars in Surgical Oncology

Volumn 11, Issue 1, 1995, Pages 60-64

  Crawford, E David ^a   Hussain, Maha ^b   Deantoni, Edward P ^a   Thompson, Ian M ^c   Eisenberger, Mario A ^d   Blumenstein, Brent ^e   Coltman, Charles A ^f  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BROOKE ARMY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Statistical Center   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

advanced disease; clinical trials; prostate cancer

Indexed keywords

FINASTERIDE; FLUTAMIDE; LEUPRORELIN; SURAMIN;

CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; HORMONAL THERAPY; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DIETHYLSTILBESTROL; DRUG THERAPY, COMBINATION; FLUTAMIDE; HUMAN; LEUPROLIDE; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SOCIETIES, MEDICAL; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE; UNITED STATES;

EID: 0028896348     PISSN: 87560437     EISSN: 10982388     Source Type: Journal    
DOI: 10.1002/ssu.2980110109     Document Type: Article

References (21)

1. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in survival
2. Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase two chemo‐thcrapeutic trials for hormone refractory prostate cancer: a southwest oncology group report
3. The importance of prognostic factors in advanced prostate cancer
4. Treatment of stage IV carcinoma of the prostate
5. Combined versus sequential chemo‐endocrine therapy in advanced prostate cancer: Final results of a Southwest Oncology Group Study
6. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer
7. A wide range of sensitivities to androgens develops in cloned Shionogi Mouse mammary tumor cells
8. Basis for hormonal management of advanced prostate cancer
9. A controlled trial of leuprolide with and without flutamide in prosta‐tic carcinoma
10. Endocrine therapy of advanced carcinoma of the prostate
11. A randomized controlled clinical trial of leuprolide and anandron versus leuprolide and placebo for advanced prostate cancer (abstract)
12. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cy‐proterone acetate
13. Double‐blind study of anandron versus placebo in stage D2 prostate cancer patients receiving buserelin
14. Orchidectomy vs. zoladex plus flutamide in patients with metastatic prostate cancer
15. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase II EORTC trial (30853)
16. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
17. Some statistical considerations for the interpretation of trials of combined androgen therapy
18. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double‐blind randomized trial
19. Suramin: a novel growth factor antagonist with activity in hormone‐refractory metastatic prostate cancer
20. Phase I trial of suramin in patients with advanced cancer (abstract)
21. Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: A retrospective study based upon 25 years of experience